Biosimilar in lymphoma treatment

Abstract

We are living in an era where the number of ageing population is increasing, as well as the demand for treating chronic conditions like cancer, cardiovascular disease, diabetes, etc. Considering the different types of cancer, lymphoma is one of the leading causes of death, with an estimated 259,793 deaths (2.6%) in 2020. Focusing on treatment with biosimilars, this review study aims to address the Rituximab biosimilars in lymphoma care. The patent of Rituximab has expired recently, resulting in concerns for patients with regard to accessibility particularly in countries with limited funding. These challenges stimulated the development and manufacturing of Rituximab biosimilars. The review also discusses the potential advantages and impacts of Rituximab biosimilars in lymphoma patients.